Citi tells investors it’s time to sell Moderna after 600%-plus stock gains

If Moderna's management responds with concrete pipeline updates, revenue acceleration, or strategic partnerships that materially narrow the gap between current valuation and forward earnings, the sell thesis could lose traction and stabilize investor positioning around a higher but justified price floor.

Absent a major catalyst or earnings surprise, Moderna's stock would plausibly drift sideways or consolidate at current levels as the Citi call becomes one voice among many, with institutional holders neither rushing to exit nor doubling down, leaving retail sentiment to drive shorter-term volatility.

If other major brokers follow with similar downgrades or if Moderna misses near-term revenue guidance, the sell recommendation could trigger a cascade of institutional rebalancing and stop-loss selling, putting downward pressure on the stock and potentially widening the valuation discount relative to biotech peers.